Cardiac Safety London

Event Date:
Wednesday 20th May 2020 - 10am – 3.30pm BST
Location:
Online Event
View ProgramView Program

To help to enrich and speed up your drug development programs, join us for a day of discovery as global experts in Cardiology, Pharmacology and Diabetes discuss the latest state of the art methods in early phase clinical research. The event will provide insight to enable better patient outcomes, efficiency, and cost-effectiveness in global drug development.

The 20th of May also is World Clinical Trials Day celebrating the anniversary of the first clinical trial by James Lind in 1747 into the causes of scurvy on board the HMS Salisbury. On this occasion, we will also showcase work from our Research Institute, our not-for-profit affiliate dedicated to academic research.


Programme

  • Updates on the CSRC white paper on cardiac safety assessments of anti-diabetic medicines
  • Waveform analysis and measurements of QT subintervals
  • Repolarization disturbances in type 1 long QT syndrome patients
  • Cardiac safety embedded in adaptive clinical trials
  • Sex differences in cardiac risk
  • Regulatory updates in drug development
  • Preclinical science and models in cardiac safety assessments
  • Modelling and statistics of pharmacodynamic markers

Click here to view the agenda

This is an online event, to express an interest in this event or to learn more details please contact Jack Wilmott on j.wilmott@richmondpharmacology.com

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more